Trial Profile

Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Nivolumab (Primary) ; Pemetrexed (Primary)
Indications Malignant-mesothelioma
Focus Adverse reactions

Most Recent Events

25 Jun 2025 Planned End Date changed from 1 Nov 2025 to 1 Nov 2026.
25 Jun 2025 Planned primary completion date changed from 1 Nov 2025 to 1 Nov 2026.
30 Apr 2025 Results assessing the feasibility and clinical outcomes of neoadjuvant nivolumab combined with platinum (cisplatin/carboplatin) and pemetrexed in patients with respectable diffuse pleural mesothelioma were published at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com